ReviewInternational journal of molecular sciences2020
Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04872036 (Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of Prognostic Biomarkers in Patients With Urothelial Carcinoma Treated With Platinum Regimens
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Multi-dimensional profiling of lactylation-related signatures for prognostic and therapeutic insights in bladder cancer.Cancer cell international · 2026Article
- Unveiling FDA-approved Drugs and Formulations in the Management of Bladder Cancer: A Review.Current pharmaceutical biotechnology · 2025Review
- Analysis of cell death-related genes to evaluate the prognostic and immunotherapeutic value in bladder cancer.Heliyon · 2024Article
- Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.European urology open science · 2023Article
- Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.Investigative and clinical urology · 2023Review
- Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.Frontiers in immunology · 2023Article
- Article
- Review
- Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy.Journal of clinical medicine · 2022Article
- CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database.Frontiers in oncology · 2022Article
- Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer.Frontiers in genetics · 2022Review
- Natural bioactive compounds: a potential therapeutic strategy to sensitize bladder cancer to cisplatin treatment?Cancer drug resistance (Alhambra, Calif.) · 2022Article
- Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.Frontiers in oncology · 2022Article
- Article
- The biological function of m6A reader YTHDF2 and its role in human disease.Cancer cell international · 2021Review
- Advances in bladder cancer biology and therapy.Nature reviews. Cancer · 2021Review
- The Dependence between Urinary Levels of Angiogenesis Factors, 8-Iso-prostaglandin F2Journal of oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the recommended treatment, with the highest level of evidence, for patients with muscle-invasive bladder cancer (MIBC). However, only a minority of patients receive this treatment, mainly due to patient comorbidities, the relatively small survival benefit, and the lack of predictive biomarkers to select those patients most likely to benefit from this multimodal approach. In addition, adjuvant chemotherapy has been recommended for patients with high-risk MIBC, although randomized trials have not provided conclusive evidence on the impact of this approach. At present, however, this situation is changing, largely due to our improved knowledge of the molecular biology of bladder cancer, which has enabled us to identify new prognostic and predictive biomarkers that can be used to select the most appropriate treatment for each patient. Moreover, new active treatments, especially immunotherapy, have shown promising results in the neoadjuvant setting. In addition, the gene expression profile of bladder tumors can be used to classify them into different subtypes, which correlate with specific clinical-pathological characteristics and with treatment response or resistance. Therefore, the main objective for the near future is to introduce these translational breakthroughs into routine clinical practice in order to personalize treatment for each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.